Xencor Xtends license to CSL
This article was originally published in Scrip
Executive Summary
Monrovia, California-based Xencor licensed its Xtend technology for extending the half-life of protein therapeutics to CSL Limited for use in the development of monoclonal antibodies against an undisclosed target.